Dr. Dimitrios Iliopoulos is the President, CEO and a co-Founder of Athos Therapeutics Inc. He started his academic career at Harvard Medical School where he was an Assistant Professor of Microbiology & Immunology. More recently, he was a tenured Associate Professor of Medicine at UCLA School of Medicine and Founder & Director of the UCLA Center for Systems Biomedicine funded by the Eli & Edythe Broad Foundation. He holds an MBA and a certificate in Finance from UCLA Anderson School of Management, a certificate on Mergers & Acquisitions from Stanford Business School and a certificate on Artificial Intelligence from MIT. He has received several national and international awards related to research on inflammation from NIH/NIDDK, the American Association for Cancer Research, the Sidney Kimmel Foundation and the Leona & Harry Helmsley Foundation for the identification of novel genes and development of drugs for patients with autoimmune diseases and cancer. He has discovered that compounds used for other diseases, such as metformin and statins, also have anti-cancer properties. He has published more than 130 scientific articles in top tier biomedical journals, having more than 17,000 citations. Furthermore, he is a member of the American Gastroenterology Association and the European Crohn’s & Colitis Organization. He developed a real options financial model for the valuation of early-stage biotechnology products and companies (Biotechnology Valuation & Investing, 2nd Edition, Iliopoulos D & Hsu J, Amazon Publishing).
